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17β-H
ydroxysteroiddehydrogenasetype1(17β-HSD1)
transforms estrone (E1) into estradiol (E2),
1,2
themostpotentnaturalligandforestrogenreceptors(ER).
3This
enzyme also catalyzes the reduction of dehydroepiandrosterone
(DHEA) into 5-androstene-3β,17β-diol (Δ
5-diol), a weaker
estrogen that becomes more important after menopause.
4 In-
hibitorsof17β-HSD1arethuspotentiallyinterestingtherapeutic
agents for the control of estrogen-dependent diseases such as
breast cancer and endometriosis.
57 During the last 30 years,
manyeﬀortsweremadeindesigningpotentinhibitorsofthiskey
steroidogenic enzyme, but it is only recently that lead candidates
have been reported with very good inhibitory activity.
814 The
presence of residual estrogenic activity associated with steroidal
inhibitors, which are often built around an estrane nucleus,
represented a major drawback in their development and their
use as therapeutic agents. From diﬀerent strategies tested for
reducing the estrogenicity of estrane derivatives in the past,
814
two approaches gave interesting results. Thus, Sterix Ltd.
1517
used a combination of an ethyl and alkylamide side chain at
positions 2 and 16 of E1, respectively, whereas Solvay Pharma-
ceuticals
1820 used another alkylamide side chain at position 15
of E1, with or without a substituent at position 2. Despite of the
strong inhibitory potential of 17β-HSD1 to treat estrogen-
dependent diseases, the validation of this pharmaceutical target
in a clinical perspective remains to be done. New potent
inhibitors with a nonestrogenic proﬁle are thus strongly needed
to validate the therapeutic approach in vivo and to engage the
ﬁrst clinical trial in humans.
The16β-(m-carbamoylbenzyl)estradiol(1;CC-156)hasalready
been reported as a potent inhibitor of 17β-HSD1.
21 Despite its
good inhibitory potency, this compound was found to stimulate
the MCF-7 and T-47D estrogen-sensitive breast cancer cell lines
in vitro, thus greatly reducing its therapeutic potential.
22 To
remove the undesirable residual estrogenic activity of E2 deriva-
tive1,weexploredtheimpactonboth17β-HSD1inhibitionand
estrogenicity of a series of small chains diﬀerently functionalized
in the replacement of the hydroxyl (OH) group at position 3. In
fact, this OH is well-known to be very important for ER binding
aﬃnity and, consequently, for producing the estrogenic eﬀect.
23
However, replacingthe 3-OH group byahydrogen atom didnot
allow a full blockade of the estrogenicity as assessed by the
proliferation of ER
+ cells,
22,24 but additional modiﬁcations must
betestedatthisposition.Furthermore,fromtheX-rayanalysisof
the crystallized complex of inhibitor 1 with 17β-HSD1, which
showed key interactions for inhibitory activity (Figure 1),
25 we
noticed that the 3-OH seems less crucial for 17β-HSD1 inhibi-
tion.Infact,threemajorinteractionswereidentiﬁedinthebinary
complex of 17β-HSD1 and inhibitor 1: The 17β-OH forms a
hydrogen bond with the Ser142, the C(O)NH2 group forms a
hydrogen bond with the peptide backbone of Phe192, and the
phenyl ring at C16 forms a ππ interaction with Tyr155.
However, contrary to E1, the natural substrate of the enzyme,
the 3-OH of 1 does not form hydrogen bonding with Glu282 or
His221. To reach a third anchoring point with an amino acid in
proximityofposition3of1,andthusobtainabetterbindingwith
17β-HSD1, as well as to remove the undesirable estrogenic
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ABSTRACT: 17β-Hydroxysteroid dehydrogenase type 1 (17
β-HSD1) represents a promising therapeutic target for breast
cancer treatment. To reduce the undesirable estrogenic activity
of potent 17β-HSD1 inhibitor 16β-(m-carbamoylbenzyl)-
estradiol (1) (IC50 = 27 nM), a series of analogues with a small
functionalized side chain at position 3 were synthesized and
tested.The3-(2-bromoethyl)-16β-(m-carbamoylbenzyl)-estra-
1,3,5(10)-trien-17β-ol (5) was found to be a potent inhibitor
(IC50 = 68 nM) for the transformation of estrone (E1) into
estradiol (E2) and, most importantly, did not stimulate the
proliferationofestrogen-sensitiveMCF-7cells,suggestingnoestrogenicactivity.Fromtheseresults,thecrucialroleofabromoalkyl
sidechainatcarbon3wasidentiﬁedfortheﬁrsttime.Thus,thisnewinhibitorrepresentsagoodcandidatewithaninterestingproﬁle
suitable for further studies including pharmacokinetic and in vivo studies.
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activity by disturbing the binding on ER, we chose diﬀerent
functional groups and diﬀerent side chain lengths that could
promote additional hydrogen bonding (alkylalcohol chains) or
hydrophobicinteractions(alkylbromidechains).Fromthestruc-
tureactivity relationship results obtained with 25 derivatives of
inhibitor 1, we have selected compounds 25 to demonstrate
the relevant results highlighted by compound 5.
Compounds2and3weresynthesizedfrom3-carboxy-estrone
(6)
26 as reported in Scheme 1 (part A). The benzylcarbamide
side chain was introduced at position 16 using an aldol con-
densation reaction with 3-formyl benzamide
27 and potassium
hydroxide.
22,28 The C17-ketone of 7 was then stereoselectively
reduced withsodiumborohydride, andthe16-exodouble bound
was reduced by a Pd on charcoal-catalyzed hydrogenation. The
3-carboxylicacidof8wasactivatedusingCastro'sreagent(BOP)
in the presence of N,N-diisopropylethylamine (DIPEA) to
promote the reduction with sodium borohydride, which give
the corresponding methyl alcohol 2. This later was brominated
using triphenylphosphine and carbon tetrabromide to give the
bromomethyl derivative 3.
Compounds 4 and 5 were synthesized from 3-vinyl-17-
dioxolane-estrone (9) (Scheme 1, part B) obtained from carbo-
nylative vinylation of estrone triﬂate followed by C17 dioxolane
protection.
29The vinyl groupwasﬁrsttransformed toalcohol by
anoxidativehydroborationreactionusingboranemethylsulﬁde
complex.
30 The alcohol 10 was then protected as benzyl ether
followedbydioxolanedeprotectioninacidconditions togive11.
The benzylcarbamide side chain was introduced at position 16
using the sequence of reactions reported above for the synthesis
of 8. The cleavage of 3-O-benzylether aﬀorded the alcohol 4,
which was brominated using triphenylphosphine and carbon
tetrabromide to give the bromoethyl derivative 5.
During the synthesis of compounds 25, two new stereo-
genic centers were generated at positions 16 and 17. Their C16
β-R and C17β-OH conﬁgurations were however easily con-
ﬁrmed by NMR spectroscopy. As illustrated with 5, the chemical
shiftsfor16R-Hand17R-H(3.17and3.84ppm)in
1HNMRare
identical to those (3.14 and 3.81 ppm) published for 16β-m-
carbamoylbenzyl-estradiol (1).
31 Similarly, in
13C NMR, the
signal at 83.0 ppm for 5 is also characteristic of the 16β-R and
17β-OH conﬁguration (83.0 ppm for 1).
Compounds 15 were tested for their ability to inhibit the
transformation of E1 into E2 by 17β-HSD1 in T-47D cells
(Table 1), a cell line well-known to express endogeneous 17
β-HSD1.
32,21 In the alcohol series, we made the observation that
Figure1. Keyinteractionsobservedinbinarycomplex(17β-HSD1/1)
and representation of new E2 derivatives modiﬁed at position 3 (25).
The scope of this side chain is dual, (1) reaching a third interaction with
an amino acid and (2) removing the undesirable estrogenic activity of
inhibitor 1.
Scheme 1
a
aReagents and conditions: (a) 3-Formyl benzamide, KOH, EtOH,
reﬂux, 0.5 h. (b) NaBH4, MeOH, CH2Cl2, room temperature, 1 h. (c)
H2, 10% Pd/C, MeOH, room temperature, 36 h. (d) (1) BOP, DIPEA,
DMF, room temperature; (2) NaBH4, MeOH, room temperature. (e)
PPh3,CBr4,CH 2Cl2,0C,1.7h.(f)(1)BH3-(CH3)2S,THF,78Cto
room temperature; (2) NaHCO3,H 2O2, room temperature, 3 h. (g)
NaH, benzylbromide, DMF, 0 C to room temperature, 18 h. (h) 10%
HCl:acetone (1:1), room temperature, 5 h.
Table 1. Inhibition of 17β-HSD1 by Compounds 15
inhibition (%)
compound no. R at 0.01 μM
a at 0.1 μM
a IC50 (nM)
b
1 OH 35 66 27 ( 4
2 CH2OH 14 37 ND
3 CH2Br 20 36 430 ( 99
4 CH2CH2OH 7 17 ND
5 CH2CH2Br 23 49 68 ( 6
aInhibitionofthetransformationof[
14C]-E1(60nM)into[
14C]-E2by
17β-HSD1 in T-47D intact cells. The experiment was performed in
triplicate(SD<(5%).Theinhibitorsweretestedattwoconcentrations
of 0.01 and 0.1 μM.
bMean ( SD of an experiment performed in
triplicate. ND, not determined.680 dx.doi.org/10.1021/ml200093v |ACS Med. Chem. Lett. 2011, 2, 678–681
ACS Medicinal Chemistry Letters LETTER
moving away the hydroxyl (OH) group from the steroid A ring
hadanegativeeﬀecton17β-HSD1inhibitionwith%ofinhibition
ranging from 66% for phenol 1 to 37% for methyl alcohol 2 and
17% for ethylalcohol 4 when tested at 0.1 μM. These results and
those obtained at 0.01 μM highlight the fact that no additional
favorable interaction was obtained with an amino acid of the
enzyme. On the other side, the bromoalkyl derivatives 3 and 5
were much more promising. In fact, the inhibitory activity of 5
(IC50 = 68 nM) was just 2.5 times lower than that of reference
inhibitor 1 (IC50= 27nM). However, themostimportant ﬁnding
was that the estrogenic activity was greatly modulated by the
presence of the C3 side chain (Figure 2). Bearing a phenol at
position 3, compound 1 clearly stimulated at each concentration
tested the proliferation of estrogen-sensitive MCF-7 cells, a breast
cancer cell line known to express ER. By adding one or two
methylene (CH2) groupsbetweentheOHandthe steroidA ring,
the estrogenicity decreased, but compounds 2 and 4 remained
with a signiﬁcant estrogenic activity. Substituting the OH by a
bromide atom also reduced the estrogenicity as illustrated with
compounds2and3.Interestingly,theadditionoftwoCH2groups
and the substitution of the OH by a bromide atom to generate 5
did not stimulate cell proliferation,suggesting no estrogenic eﬀect
at the three concentrations tested.
The results presented above identiﬁed the importance of a
bromoethyl side chain at position 3 in modulating both the 17
β-HSD1inhibitionactivity andtheestrogenicactivityofourlead
compound 1, but these results also raise the question of the
mechanism of action of compound 5. For the estrogenic activity,
because substituting the E2 nucleus generally reduces ER bind-
ing, especiallywhenreplacing the 3-OH, we expected to obtain a
reductionofestrogenicactivity forour E2derivatives.Ithowever
remainstobedeterminedwhetherthepresenceinposition3ofa
bromoethyl groupalone issuﬃcientto block the estrogenicity of
E2 nucleus. It is also possible that the combined eﬀect of two
chains, a bromoethyl at position 3 and a carbamoylbenzyl at
position16,isnecessarytocompleteblockageofestrogeniceﬀect
measured in vitro on ER
+ MCF-7 cells.
Forinhibitionof17β-HSD1activity,thealkylatingpropertyof
alkyl bromidesuggests the possible formationof acovalent bond
between a nucleophilic amino acid residue of the enzyme and
compound 5 (irreversible inhibitor) by a nucleophilic substitu-
tion of the bromide. However, the alkylating property of
bromoalkyls is greatly variable according to the environment
and the nature of the alkyl moiety, and our bromoethyl inhibitor
5 is much more stable with a less alkylating (electrophilic)
potency than a bromobenzyl derivative such as 3. So, it is also
possible that the hydrophobic bromoethyl side chain interacts
reversibly with an hydrophobic pocket, such as this identiﬁed by
Lawrenceetal.
15intheproximityofposition2ofnaturalenzyme
substrate or another hydrophobic pocket that remains to be
identiﬁed. It can also be highlighted that the X-ray analysis of
crystallized binary complex of 1 with 17β-HSD1 showed no
interaction of 3-OH with Glu282 or His221, which can be
explained by the presence of three interactions between the
16β-side chain and the17β-OH with the enzyme that slightly
moves the inhibitor toward the right side. Transposed to the
inhibitor 5, this could free up space to accommodate the
bromoethyl group added at position 3. Whatever the case, it is
clear that additional experiments such as enzyme kinetic and
crystallization studies will be necessary to properly address all of
the questions regarding the mechanism of 17β-HSD1 by new
inhibitor 5.
In conclusion, we have successfully synthesized a series of
C3-functionalized derivatives of the potent 17β-HSD1 in-
hibitor 1. The bromoethyl side chain generated the most
active inhibitor, compound 5, thus demonstrating the good
tolerance of 17β-HSD1 for a hydrophobic chain introduced
at position 3 of this steroid nucleus. Most importantly, the
addition of this small chain removed the residual estrogenic
activity of 1. A more complete investigation of the crucial C3
side chain by the study of diﬀerent spacers and a larger
diversity of chemical groups [NR1R2,N C ( O ) R ,F ,C l ,I ,a n d
Ph] is ongoing in our laboratory and will be reported in due
course. However, with a very good inhibitory activity (IC50 =
68 nM) and no estrogenic eﬀect observed on estrogen-
sensitive breast cancer cells, compound 5 represents a good
candidate with an interesting proﬁle suitable for further
studies including pharmacokinetic and in vivo studies.
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Figure 2. Eﬀect of inhibitors 15 on the growth of estrogen-starved
estrogen-sensitive (ER
+) MCF-7 cells after 7 days of treatment. The
proliferation of control cells is ﬁxed at 100%. Results are expressed as
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